论文部分内容阅读
目的观察胰激肽原酶肠溶片与贝那普利联合应用对早期糖尿病肾病的临床疗效。方法选择我院门诊及住院的2型糖尿病肾病患者126例,根据患者24h尿白蛋白排泄率分为两组,治疗组采用胰激肽原酶肠溶片联合贝那普利治疗,对照组单用贝那普利,共12周。比较治疗前后两组患者的体重指数(BMI)、空腹血糖(FPG)、空腹血清胰岛素水平(FINS)、血肌酐(SCR)、24h尿白蛋白排泄率(UAER)、糖化血红蛋白(HbA1C)、血压(BP)等指标的变化。结果治疗组降低2型糖尿病肾病患者的UAER显著优于对照组,差值具有统计学意义(P<0.05)。结论对于早期的2型糖尿病肾病患者,两者联合应用,比单独应用贝那普利能够更有效地减少患者的UAER,延缓病情进展。
Objective To observe the clinical effect of pancreatic kallikrein combined with benazepril on early diabetic nephropathy. Methods 126 patients with type 2 diabetic nephropathy in our hospital and inpatient were divided into two groups according to urinary albumin excretion rate of 24 hours. The treatment group was treated with pancreatic kallikrein combined with benazepril and the control group With benazepril, a total of 12 weeks. The body mass index (BMI), fasting blood glucose (FPG), fasting serum insulin (FINS), serum creatinine (SCR), urinary albumin excretion rate (UAER), HbA1C, (BP) and other indicators of change. Results In the treatment group, the UAER of patients with type 2 diabetic nephropathy was significantly better than that of the control group, with a significant difference (P <0.05). Conclusions For patients with early type 2 diabetic nephropathy, the combination of the two can reduce the UAER and delay the progression of the disease more effectively than benazepril alone.